Companies
DYNEX Technologies
the DS2 Elite, introduced as the next generation of the established DS2 automated ELISA processing platform, is positioned to elevate laboratory performance for fully automated ELISA processing across laboratories and research clinics of all sizes.
- Country
- United States
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| analytics-pat | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | 100 samples per load; 2 plates; up to 8 reagents (25 mL) or 10 reagents (15 mL); 24 control bottles; 216 sample tips; 20 reagent tips; up to 96 deep-well strips | 39782142.hs-sites.com · dynextechnologies.com |
| Certification | ISO certified | dynextechnologies.com |
| Regulatory approval | FDA registered and regulated; CE Mark compliant | dynextechnologies.com |
| Production site | United States | dynextechnologies.com |
| Headcount | 80-124 employees medium confidence | incfact.com · datanyze.com |
| Revenue | $1M-$100 million annually medium confidence | incfact.com · datanyze.com |
Independent sources: 39782142.hs-sites.com · datanyze.com · incfact.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Automated ELISA analyzers | analytics-pat | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.